Akebia Therapeutics Signs A Multi-Year Commercial Contract With One Of The Nation's Leading Providers Of Kidney Care Services, Expanding Access To Vafseo For Patients On Dialysis; The Contract Enables Physicians To Prescribe Vafseo To Patients On Dialysis As Deemed Clinically Appropriate;' Akebia Expects Vafseo Will Be Available In The U.S. In January 2025.
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics has signed a multi-year commercial contract with a leading kidney care provider to expand access to its drug Vafseo for dialysis patients. The drug is expected to be available in the U.S. by January 2025.
October 22, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics has secured a significant partnership with a major kidney care provider, enhancing the market potential for its drug Vafseo, which will be available in the U.S. in January 2025.
The partnership with a leading kidney care provider significantly expands the potential market for Vafseo, a key product for Akebia. This is likely to positively impact Akebia's stock as it opens up a large patient base and enhances revenue prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100